Anusha Ramachandran
Director of CMC Operations Convergent Therapeutics, Inc
Anusha Ramachandran is Senior Director of CMC Operations at Convergent Therapeutics, where she leads manufacturing and CMC strategy to advance innovative therapeutic programs from development through clinical execution. With more than a decade of experience spanning Convergent Therapeutics, Strand Therapeutics, ElevateBio, bluebird bio, and Axcella Health, she has built deep expertise in manufacturing operations, technology transfer, process development, GMP production, and supply chain management across the biotechnology sector.
Wednesday 16th September 2026
Securing Actinium Supply Through Emerging Production Pathways & Strategic Partnerships to Overcome the Alpha Isotope Bottleneck
10:00 am
- Exploring emerging production pathways (thorium extraction, accelerator-based methods, reactor routes) and assessing their scalability and commercial viability
- Strategizing long-term supply agreements and partnership models to secure access to Ac-225 in a competitive and supply-constrained environment
- Managing quality and regulatory considerations associated with Ac-225 production, including handling impurities such as Ac-227 and downstream QC implications
Wednesday 16th September 2026
Panel Discussion: Why 2026 Is the Year the Gap Between Clinical Ambition & Operational Capacity Must Begin to Close
9:15 am
- Panelists will examine the state of the radiopharmaceutical supply chain in 2026: where infrastructure investment is landing, where the workforce deficit is most acute, and how the shift in isotope preferences – from the established beta emitters toward alphas and emerging candidates – is creating new pressure across every manufacturing echelon
- Discussing the compounding risks that arise as programs progress into Phase II/III, where reliance on limited isotope supply, third-party manufacturing, logistics, and fragmented coordination from CDMO through to bedside must be managed in parallel to avoid disruption to clinical delivery
- Discuss what ‘commercial readiness’ actually means for radiopharmaceuticals and why the industry’s collective definition has to evolve beyond approval to include reliable, scalable, and distributed supply at the patient level
